Model of collective detachment in high-grade serous ovarian cancer demonstrates that tumor spheroids produce ECM to support metastatic processes

被引:5
|
作者
Micek, Hannah M. [1 ]
Rosenstock, Lauren [1 ]
Ma, Yicheng [1 ]
Hielsberg, Caitlin [1 ]
Montemorano, Lauren [2 ]
Gari, Metti K. [3 ,4 ]
Ponik, Suzanne M. [4 ,5 ]
Kreeger, Pamela K. [1 ,2 ,4 ,5 ]
机构
[1] Univ Wisconsin Madison, Dept Biomed Engn, Madison, WI 53705 USA
[2] Univ Wisconsin, Dept Obstet & Gynecol, Sch Med & Publ Hlth, Madison, WI 53705 USA
[3] Univ Wisconsin, Mol & Cellular Pharmacol Training Program, Sch Med & Publ Hlth, Madison, WI 53705 USA
[4] Univ Wisconsin, Dept Cell & Regenerat Biol, Sch Med & Publ Hlth, Madison, WI 53705 USA
[5] Univ Wisconsin, Carbone Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53705 USA
关键词
EXTRACELLULAR-MATRIX; MESOTHELIAL CELLS; ADHESION; EXPRESSION; ASCITES;
D O I
10.1063/5.0132254
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
High-grade serous ovarian cancer (HGSOC) metastasizes through transcoelomic spread, with both single cells and spheroids of tumor cells observed in patient ascites. These spheroids may form through single cells that detach and aggregate (Sph-SC) or through collective detachment (Sph-CD). We developed an in vitro model to generate and separate Sph-SC from Sph-CD to enable study of Sph-CD in disease progression. In vitro-generated Sph-CD and spheroids isolated from ascites were similar in size (mean diameter 51 vs 55 mu m, p > 0.05) and incorporated multiple ECM proteins. Using the in vitro model, nascent protein labeling, and qRT-PCR, we determined that ECM was produced after detachment. As fibronectin plays a key role in many cell adhesion events, we confirmed that inhibiting RGD-based adhesion or fibronectin assembly reduced Sph-CD-mesothelial adhesion strength under shear stress. Our model will enable future studies to determine factors that favor formation of Sph-CD, as well as allow investigators to manipulate Sph-CD to better study their effects on HGSOC progression.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome
    Clifford, Cole
    Vitkin, Natasha
    Nersesian, Sarah
    Reid-Schachter, Gillian
    Francis, Julie-Ann
    Koti, Madhuri
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2018, 80 (02)
  • [42] Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
    Zhao, Li
    Corvigno, Sara
    Ma, Shaolin
    Celestino, Joseph
    Fleming, Nicole D.
    Hajek, Richard A.
    Ahumada, Adrian Lankenau
    Jennings, Nicholas B.
    Thompson, Erika J.
    Tang, Hongli
    Westin, Shannon N.
    Jazaeri, Amir A.
    Zhang, Jianhua
    Futreal, P. Andrew
    Sood, Anil K.
    Lee, Sanghoon
    CANCERS, 2022, 14 (15)
  • [43] Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer
    Silva, Romina
    Glennon, Kate
    Metoudi, Michael
    Moran, Bruce
    Salta, Sofia
    Slattery, Karen
    Treacy, Ann
    Martin, Terri
    Shaw, Jacqui
    Doran, Peter
    Lynch, Lydia
    Jeronimo, Carmen
    Perry, Antoinette S.
    Brennan, Donal J.
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 120 - 132
  • [44] Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer
    Davis, Sally J.
    Sheppard, Karen E.
    Pearson, Richard B.
    Campbell, Ian G.
    Gorringe, Kylie L.
    Simpson, Kaylene J.
    CLINICAL CANCER RESEARCH, 2013, 19 (06) : 1411 - 1421
  • [45] Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer-The Possibility or the Necessity?
    Wilczynski, Jacek
    Paradowska, Edyta
    Wilczynski, Milosz
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):
  • [46] Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
    Gronauer, Raphael
    Madersbacher, Leonie
    Monfort-Lanzas, Pablo
    Floriani, Gabriel
    Sprung, Susanne
    Zeimet, Alain Gustave
    Marth, Christian
    Fiegl, Heidelinde
    Hackl, Hubert
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [47] AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
    Hojnik, Marko
    Suster, Natasa Kenda
    Smrkolj, Spela
    Sisinger, Damjan
    Grazio, Snjezana Frkovic
    Verdenik, Ivan
    Rizner, Tea Lanisnik
    CANCERS, 2022, 14 (03)
  • [48] Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer
    Wada, Miku
    Kukita, Asako
    Sone, Kenbun
    Hamamoto, Ryuji
    Kaneko, Syuzo
    Komatsu, Masaaki
    Takahashi, Yu
    Inoue, Futaba
    Kojima, Machiko
    Honjoh, Harunori
    Taguchi, Ayumi
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Tsuruga, Tetsushi
    Mori-Uchino, Mayuyo
    Wada-Hiraike, Osamu
    Osuga, Yutaka
    Fujii, Tomoyuki
    BIOMOLECULES, 2020, 10 (12) : 1 - 12
  • [49] CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma
    Mei, Jie
    Tian, Huixiang
    Huang, Hsuan-Shun
    Wu, Nayiyuan
    Liou, Yu-Ligh
    Chu, Tang-Yuan
    Wang, Jing
    Zhang, Wei
    CELL CYCLE, 2023, 22 (01) : 85 - 99
  • [50] HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
    Ali, Ahlam
    Zhang, Fengyu
    Maguire, Aaron
    Byrne, Tara
    Weiner-Gorzel, Karolina
    Bridgett, Stephen
    O'Toole, Sharon
    O'Leary, John
    Beggan, Caitlin
    Fitzpatrick, Patricia
    McCann, Amanda
    Furlong, Fiona
    CANCERS, 2020, 12 (12) : 1 - 20